Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price was up 7% during trading on Tuesday . The company traded as high as $8.45 and last traded at $8.45, with a volume of 52,233 shares traded. The stock had previously closed at $7.90.

A number of equities analysts recently issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $17.00 price target on shares of Oxford Immunotec Global PLC in a report on Monday, June 27th. Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday, July 6th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th.

The stock’s 50-day moving average price is $8.86 and its 200 day moving average price is $9.83. The firm’s market capitalization is $190.23 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.32). During the same period in the previous year, the business posted ($0.31) earnings per share. The business earned $17.10 million during the quarter, compared to analyst estimates of $16.96 million. The firm’s quarterly revenue was up 23.9% on a year-over-year basis. On average, analysts anticipate that Oxford Immunotec Global PLC will post ($1.28) EPS for the current fiscal year.

An institutional investor recently raised its position in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. boosted its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned 4.74% of Oxford Immunotec Global PLC worth $12,293,000 as of its most recent filing with the SEC.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.